Literature DB >> 7010651

Preoperative irradiation for head and neck cancer: results of a prospective study.

J J Terz, E R King, W Lawrence.   

Abstract

Two hundred forty-eight patients with primary epidermoid carcinoma of the oral cavity, oropharynx, and hypopharynx, stages II, III, and IV were entered into a prospective randomized clinical trial of preoperative irradiation therapy (700 rads X 2) and surgery versus surgery alone. At 5 years both groups had a similar survival when analyzed according to stage of disease, primary site, or lymph node status. However, the group of patients receiving preoperative irradiation showed a lower incidence of local recurrence (22% versus 36%) preoperative irradiation showed a lower incidence of local recurrence (22% versus 36%) (P = 0.02). From this study we conclude that preoperative irradiation in this dose schedule has little influence on the ultimate outcome after surgical treatment of head and neck cancer.

Entities:  

Mesh:

Year:  1981        PMID: 7010651

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

Review 1.  Radiation enhancement of metastasis: a review.

Authors:  C F von Essen
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

Review 2.  Controversies in management of the neck in head and neck cancer.

Authors:  Madhur Garg; Jonathan J Beitler
Journal:  Curr Treat Options Oncol       Date:  2004-02

3.  Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment.

Authors:  Vishal M Bulsara; Helen V Worthington; Anne-Marie Glenny; Janet E Clarkson; David I Conway; Michaelina Macluskey
Journal:  Cochrane Database Syst Rev       Date:  2018-12-24

4.  Perioperative complications of total en bloc spondylectomy: adverse effects of preoperative irradiation.

Authors:  Noriaki Yokogawa; Hideki Murakami; Satoru Demura; Satoshi Kato; Katsuhito Yoshioka; Hiroyuki Hayashi; Takayoshi Ishii; Takashi Igarashi; Xiang Fang; Hiroyuki Tsuchiya
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.